Dianthus Therapeutics (DNTH) Expected to Announce Earnings on Tuesday

Dianthus Therapeutics (NASDAQ:DNTH) is anticipated to announce its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect the company to announce earnings of ($0.97) per share and revenue of $0.3980 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 4:00 PM ET.

Dianthus Therapeutics Price Performance

Shares of DNTH opened at $65.20 on Friday. The firm has a 50-day simple moving average of $48.42 and a two-hundred day simple moving average of $40.65. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $65.50. The stock has a market cap of $2.82 billion, a PE ratio of -18.74 and a beta of 1.56.

Analysts Set New Price Targets

A number of brokerages recently weighed in on DNTH. HC Wainwright upped their price objective on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Wedbush lifted their target price on shares of Dianthus Therapeutics from $46.00 to $55.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Jefferies Financial Group upped their price target on shares of Dianthus Therapeutics from $66.00 to $81.00 and gave the company a “buy” rating in a report on Monday, February 2nd. Finally, Truist Financial increased their price target on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $67.63.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DNTH. Raymond James Financial Inc. purchased a new position in Dianthus Therapeutics in the 2nd quarter valued at about $27,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Dianthus Therapeutics during the 4th quarter worth about $40,000. Russell Investments Group Ltd. purchased a new stake in shares of Dianthus Therapeutics during the third quarter worth about $64,000. Tower Research Capital LLC TRC grew its holdings in shares of Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after buying an additional 3,317 shares in the last quarter. Finally, Royal Bank of Canada raised its position in shares of Dianthus Therapeutics by 36.9% in the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after buying an additional 542 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.